Applied Genetic Technologies Corporation (AGTC), a clinical-stage biotechnology company, develops gene therapy products for inherited orphan ophthalmology diseases.
AGTC's lead product candidates in the preclinical stage comprise treatments for X-linked retinoschisis, Congenital Achromatopsia, and X-linked retinitis pigmentosa, which are diseases of the eye caused by mutations in single genes. It also has completed preclinical proof-of-concept studies, and Phase I and Phase II clinical trials of a treatment for alpha-1 antitrypsin deficiency, an inherited orphan lung disease. In addition, the company has proof-of-concept programs for other eye diseases, such as leber congenital amaurosis (type 2), and wet form of age-related macular degeneration. It has strategic collaboration agreements with SAFC Pharma; and 4D Molecular Therapeutics.
The company was founded in 1999 and is headquartered in Alachua, Florida.
November 11, 2022
RegMed Investors’ (RMi) pre-open: post massive gains, what usually follows is pain
November 10, 2022
RegMed Investors’ (RMi) closing bell: the risk-on fervor sent markets skyward and sector upward
November 10, 2022
RegMed Investors’ (RMi) pre-open: CPI, up +0.4% versus +0.6% estimate
November 9, 2022
RegMed Investors’ (RMi) closing bell: down sliding markets and sector responds to incomplete election results
November 9, 2022
RegMed Investors’ (RMi) pre-open: stock futures trade lower as election results are tallied
November 8, 2022
RegMed Investors’ (RMi) closing bell: after five (5) down sessions, it was inevitable that the algorithms would “rule”
November 8, 2022
RegMed Investors’ (RMi) pre-open: vote your conscious and your portfolio
November 7, 2022
RegMed Investors’ (RMi) closing bell: election and economics will determine the week as negative momentum moves the sector today
November 7, 2022
RegMed Investors’ (RMi) pre-open: the cell and gene therapy sector is stuck in earnings LPS (loss-per-share) season
November 4, 2022
RegMed Investors’ (RMi) closing bell: strolling a crooked session (10 of 35 covered companies stumbled)
35 companies, 1 interpreter!
Insight, foresight and recommendation
Applied Genetics Technology Corporations (AGTC) In Q1/16, AGTC has clinical trial timing issues and spending woes – until clinical results are announced which are slow due to enrollments ...
holdMy motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.
My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.
Do you have an opinion you would like to share with us? We would like to hear from you.
Please e-mail us at hwm@regmedinvestors.com.
Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors